603 reports of this reaction
3.8% of all AMPICILLIN reports
#3 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #3 most commonly reported adverse reaction for AMPICILLIN, manufactured by Armas Pharmaceuticals Inc.. There are 603 FDA adverse event reports linking AMPICILLIN to DRUG HYPERSENSITIVITY. This represents approximately 3.8% of all 15,856 adverse event reports for this drug.
Patients taking AMPICILLIN who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is moderately reported among AMPICILLIN users, representing a notable but not dominant share of adverse events.
In addition to drug hypersensitivity, the following adverse reactions have been reported for AMPICILLIN:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 603 FDA reports for AMPICILLIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 3.8% of all adverse event reports for AMPICILLIN, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking AMPICILLIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.